FINWIRES · TerminalLIVE
FINWIRES

Arrowhead Signs Deal With Madrigal to License Clinical MASH Program

By

Arrowhead Pharmaceuticals (ARWR) said Tuesday it has signed an agreement with Madrigal Pharmaceuticals (MDGL) to exclusively license its ARO-PNPLA3 program, which is evaluating a potential treatment for metabolic dysfunction-associated steatohepatitis, or MASH.

Under the agreement, Arrowhead said that Madrigal will receive a global license to develop, manufacture, and commercialize ARO-PNPLA3, which uses the TRiM platform to silence hepatocyte expression of patatin-like phospholipase domain-containing 3, or PNPLA3, as a potential treatment for patients with MASH.

When the deal closes, Arrowhead said it will receive a $25 million upfront payment and be eligible to receive up to an additional $975 million upon meeting development, regulatory, and sales milestones.

Arrowhead said it is also eligible to receive tiered royalties on commercial sales ranging from high single digits to the mid-teens.

Price: $76.58, Change: $+0.19, Percent Change: +0.25%

Related Articles

Wire

IAC Q1 Loss Narrows, Revenue Falls; Shares Drop After Hours

IAC (IAC) reported a Q1 loss late Monday of $0.94 per diluted share, narrowing from the loss of $2.64 a year earlier.Analysts polled by FactSet expected a loss of $0.37.Revenue in the three months ended March 31 fell to $422.9 million from $481.7 million a year earlier.Analysts surveyed by FactSet expected $520.3 million.IAC shares fell 8.6% in after-hours trading.

$IAC
Wire

Vornado Realty Trust Q1 Non-GAAP FFO, Revenue Fall; Shares Drop After Hours

Vornado Realty Trust (VNO) reported Q1 non-GAAP funds from operations late Monday of $0.52 per diluted share, down from $0.63 a year earlier.Analysts polled by FactSet expected $0.51.Revenue in the three months ended March 31 fell to $459.1 million from $461.6 million a year earlier.Analysts surveyed by FactSet expected $431.7 million.Vornado shares fell 3% in after-hours trading.

$VNO
Wire

GeneDx Q1 Swings to Adjusted Loss, Revenue Rises; 2026 Revenue Guidance Lowered; Shares Fall

GeneDx (WGS) reported Monday Q1 adjusted loss of $0.28 per diluted share, swinging from an adjusted earnings of $0.31 a year earlier.Analysts polled by FactSet expected loss of $0.02.Revenue for the quarter ended March 31 was $102.3 million, up from $87.1 million a year earlier.Analysts surveyed by FactSet expected $112.5 million.For Q2, the company expects revenue of $110 million to $112 million. Analysts expect $130.3 million.The company now expects 2026 revenue of $475 million to $490 million, down from $540 million to $555 million expected earlier. Analysts expect $550.0 million.Shares of the company were down over 45% during after-hours activity.

$WGS